치매성 운동장애 증후군 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(-2031년) - 치료에 사용되는 약물별, 지역별

Treatment Syndromes Dementia Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 7,168,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 12,192,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 15,213,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

전 세계 치매 및 운동장애 관련 증후군 치료제 시장 규모는 최근 몇 년 동안 괄목할 만한 성장세를 보이고 있습니다. 치매와 파킨슨병을 포함한 운동장애는 전 세계 환자와 간병인 모두에게 큰 도전이 되고 있습니다. 최근 자료에 따르면, 파킨슨병과 같은 운동장애를 앓고 있는 환자의 약 80%가 결국 인지장애를 앓고 있는 것으로 나타나 효과적인 치료법의 필요성이 더욱 강조되고 있습니다.

전 세계적으로 고령화가 진행되면서 치매 환자 수가 증가하고 있습니다. 이러한 급증으로 인해 의료 서비스 제공자들은 재택 간호 서비스, 성인 데이케어 서비스, 심리 치료, 약물 치료, 말기 치매 환자를 위한 의료기기 등 다양한 해결책을 모색하고 있습니다. 완화의료 병동도 환자와 가족들의 요구에 따라 크게 성장하고 있습니다.

그러나 치매와 운동장애를 앓고 있는 사람들의 부담을 줄이기 위한 노력에도 불구하고 몇 가지 과제가 남아있습니다. 이러한 과제에는 엄격한 규제 프레임워크, 의약품 승인 과정의 관료적 장애물, 연구개발을 위한 자금 부족, 효과적인 치료 관리 방법을 찾기 위한 지속적인 투쟁 등이 포함됩니다. 이러한 질병을 치료하기 위해 고안된 대부분의 약물이 임상 3상 시험을 통과하지 못해 실행 가능한 치료법을 찾는 데 어려운 장애물이 되고 있다는 점은 주목할 만합니다.

본 보고서는 세계 치매성 운동장애 증후군 치료 시장에 대해 조사했으며, 시장 개요와 함께 치료에 사용되는 약품별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 치매성 운동장애 증후군 치료 시장 전망, 2018-2031년

• 세계의 치매성 운동장애 증후군 치료 시장 전망, 진행성 치매 치료에 사용되는 약제별, 금액(10억 달러), 2018-2031년
• 세계의 치매성 운동장애 증후군 치료 시장 전망, 기타 신경학적 이상을 수반하는 진행성 치매 치료에 사용되는 약제별, 금액(10억 달러), 2018-2031년
• 세계의 치매성 운동장애 증후군 치료 시장 전망, 운동장애 증후군 치료에 사용되는 약제별, 금액(달러), 2018년에서 2031년
• 세계의 치매성 운동장애 증후군 치료 시장 전망, 지역별, 금액(10억 달러), 2018-2031년

제4장 북미의 치매성 운동장애 증후군 치료 시장 전망, 2018-2031년

제5장 유럽의 치매성 운동장애 증후군 치료 시장 전망, 2018-2031년

제6장 아시아태평양의 치매성 운동장애 증후군 치료 시장 전망, 2018-2031년

제7장 라틴아메리카의 치매성 운동장애 증후군 치료 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 치매성 운동장애 증후군 치료 시장 전망, 2018-2031년

제9장 경쟁 상황

• 운동장애 증후군 치료에 사용되는 약제별 vs 기타 신경학적 이상을 수반하는 진행성 치매 치료에 사용되는 약제별 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁력 대시보드
• 기업 개요
  • F. Hoffmann-La Roche, Ltd.
  • Baxter
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi
  • Pfizer, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • AstraZeneca GmbH
  • Abbott Laboratories, Inc.
  • Bristol-Myers Squibb Company

제10장 부록

ksm

영문 목차

영문목차

Leading Pharmaceutical Companies Aim to Address Rising Incidence of Cognitive Defects

The global market for the treatment of syndromes related to dementia and movement disorders has witnessed remarkable growth in recent years, as the number of individuals affected by these conditions continues to rise. Dementia, a broad category of mental illnesses, and movement disorders, including Parkinson's disease, have presented significant challenges for both patients and caregivers worldwide. According to recent data, approximately 80% of people with movement disorders such as Parkinson's ultimately develop cognitive defects, further emphasizing the need for effective treatments.

Key Market Dynamics:

The increasing aging population across the globe is a driving force behind the rising number of dementia cases. This surge in cases has prompted healthcare providers to explore a range of solutions, including home care services, adult day care services, psychological therapies, medication, and medical devices tailored for last-stage dementia patients. Palliative care units are also witnessing significant growth in response to the demands of patients and their families.

However, despite the collective efforts to ease the burden on those affected by dementia and movement disorders, several challenges persist. These challenges include a stringent regulatory framework, bureaucratic hurdles in the drug approval process, insufficient funding for research and development, and the ongoing struggle to find effective therapeutic management methods. It is noteworthy that most drugs designed to treat these conditions fail to pass Phase III testing, creating a daunting roadblock in the quest to find viable treatments.

Regional Analysis:

Geographically, the North America region is expected to maintain its dominance in the global market for the treatment of syndromes associated with dementia and movement disorders. This dominance is driven by the growing aging population and the increasing incidence of neurodegenerative diseases. Over the next six years, the Asia region is also projected to experience higher growth rates in this market, signaling the need for innovative solutions to meet the rising demand.

Key Market Players:

Major companies at the forefront of the global market for the treatment of dementia and movement disorders include Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, and Pfizer, among others. These industry leaders are dedicated to developing innovative treatments to address the complex challenges presented by these debilitating conditions.

Segment Analysis:

The global market for the treatment of syndromes related to dementia and movement disorders is categorized based on the drugs used for treatment, including progressive dementia, movement disorders, and progressive dementia with certain other neurological abnormalities. These segments encompass drugs tailored for specific conditions, diseases-based therapeutics, and those designed to address associated neurological abnormalities.

As the global community grapples with the growing burden of dementia and movement disorders, the healthcare and pharmaceutical industries are committed to advancing research and delivering effective treatments that enhance the quality of life for affected individuals and their families.

By Drugs Used to Treatment Progressive Dementia

• Diseases Based Therapeutics Under Progressive Dementia
• Drugs for Progressive Dementia

By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities

• Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
• Drugs for Progressive Dementia

By Drugs Used to Treat Movement Disorder Syndrome

• Diseases Based Therapeutics Under Movement Disorder Syndrome
• Drugs for Movement Disorder Syndrome

By Region

• North America
• Europe
• Asia

Table of Contents

1. Executive Summary

• 1.1. Global Treatment Syndromes Dementia Movement Disorders Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

• 3.1. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
    • 3.1.1.2. Drugs for Progressive Dementia
• 3.2. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
    • 3.2.1.2. Drugs for Progressive Dementia
• 3.3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
    • 3.3.1.2. Drugs for Movement Disorder Syndrome
• 3.4. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. North America
    • 3.4.1.2. Europe
    • 3.4.1.3. Asia Pacific
    • 3.4.1.4. Latin America
    • 3.4.1.5. Middle East & Africa

4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

• 4.1. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
    • 4.1.1.2. Drugs for Progressive Dementia
• 4.2. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
    • 4.2.1.2. Drugs for Progressive Dementia
• 4.3. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
    • 4.3.1.2. Drugs for Movement Disorder Syndrome
• 4.4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.4.1. Key Highlights
    • 4.4.1.1. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 4.4.1.2. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 4.4.1.3. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 4.4.1.4. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 4.4.1.5. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 4.4.1.6. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

• 5.1. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
    • 5.1.1.2. Drugs for Progressive Dementia
• 5.2. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
    • 5.2.1.2. Drugs for Progressive Dementia
• 5.3. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
    • 5.3.1.2. Drugs for Movement Disorder Syndrome
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis
• 5.4. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.4.1.2. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.4.1.3. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.1.4. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.4.1.5. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.4.1.6. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.1.7. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.4.1.8. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.4.1.9. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.1.10. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.4.1.11. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.4.1.12. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.1.13. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.4.1.14. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.4.1.15. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.1.16. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.4.1.17. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.4.1.18. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.1.19. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.4.1.20. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.4.1.21. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
    • 6.1.1.2. Drugs for Progressive Dementia
• 6.2. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
    • 6.2.1.2. Drugs for Progressive Dementia
• 6.3. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
    • 6.3.1.2. Drugs for Movement Disorder Syndrome
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis
• 6.4. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.4.1.2. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.4.1.3. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.1.4. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.4.1.5. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.4.1.6. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.1.7. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.4.1.8. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.4.1.9. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.1.10. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.4.1.11. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.4.1.12. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.1.13. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.4.1.14. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.4.1.15. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.1.16. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.4.1.17. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.4.1.18. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

• 7.1. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
    • 7.1.1.2. Drugs for Progressive Dementia
• 7.2. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
    • 7.2.1.2. Drugs for Progressive Dementia
• 7.3. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
    • 7.3.1.2. Drugs for Movement Disorder Syndrome
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis
• 7.4. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 7.4.1.2. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 7.4.1.3. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.4.1.4. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 7.4.1.5. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 7.4.1.6. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.4.1.7. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 7.4.1.8. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 7.4.1.9. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.4.1.10. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 7.4.1.11. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 7.4.1.12. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
    • 8.1.1.2. Drugs for Progressive Dementia
• 8.2. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
    • 8.2.1.2. Drugs for Progressive Dementia
• 8.3. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
    • 8.3.1.2. Drugs for Movement Disorder Syndrome
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis
• 8.4. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.4.1.2. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.4.1.3. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.4.1.4. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.4.1.5. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.4.1.6. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.4.1.7. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.4.1.8. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.4.1.9. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.4.1.10. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.4.1.11. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.4.1.12. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.4.1.13. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.4.1.14. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.4.1.15. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. By Drugs Used to Treat Movement Disorder Syndrome vs By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities Heat map
• 9.2. Company Market Share Analysis, 2023
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. F. Hoffmann-La Roche, Ltd.
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. Baxter
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. Novartis AG
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. Merck & Co., Inc.
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Sanofi
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Pfizer, Inc.
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Valeant Pharmaceuticals International, Inc.
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. AstraZeneca GmbH
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. Abbott Laboratories, Inc.
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Bristol-Myers Squibb Company
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Product Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료